Xilio Therapeutics, Inc.XLONASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P32
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -6.58% |
| Q2 2025 | 85.46% |
| Q1 2025 | -6.45% |
| Q4 2024 | -17.87% |
| Q3 2024 | -4.07% |
| Q2 2024 | 7.85% |
| Q1 2024 | -11.38% |
| Q4 2023 | 6.20% |
| Q3 2023 | -16.39% |
| Q2 2023 | -18.06% |
| Q1 2023 | 7.56% |
| Q4 2022 | 15.03% |
| Q3 2022 | -19.75% |
| Q2 2022 | 8.89% |
| Q1 2022 | 31.43% |
| Q4 2021 | 8.42% |
| Q3 2021 | -41.00% |
| Q2 2021 | 52.70% |
| Q1 2021 | -34.22% |
| Q4 2020 | 54.16% |
| Q3 2020 | 25.29% |
| Q2 2020 | 62.30% |
| Q1 2020 | 0.00% |